Glenmark Pharmaceuticals Ltd

NSE: GLENMARK · BSE: 532296 · Pharmaceuticals & Biotechnology · 39 announcements

Glenmark Pharmaceuticals Ltd news stories on ALFA NewsRead the news →

Share price: ₹2,293.50
Market cap: ₹64,728 Cr
Revenue (annual): ₹16,983 Cr
Net profit (annual): ₹1,362 Cr
P/E (TTM): 36.0×Sector 47.4×
Promoter holding: 46.65%+0.00% QoQ
FII holding: 20.89%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

29 May 2026 20:52 IST BSE

Glenmark Pharmaceuticals Merger & Restructuring Worth ₹223 Cr

Glenmark Pharmaceuticals approved transferring its Nebulizer portfolio to its subsidiary for ₹223 Crore. The restructuring aims to enhance strategic focus and respiratory innovation leadership.

Value: ₹223.0 Cr
Execution: Expected completion on or before 30th June 2026

Read the filing ↗